Dabigatran etexilate is a double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran, a potent thrombin inhibitor Dabigatran also inhibits trypsin, but only weakly inhibits other serine proteases. The prodrug dabigatran etexilate shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action. It is not metabolized by cytochrome P450 isozymes and has a low potential for drug-drug interactions.
API's & Drug Standards
Send us your enquiry for Dabigatran Etexilate. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Dabigatran Etexilate email us and we will include your contribution on the website.